BMS-663068 - CAS 864953-29-7
Catalog number: 864953-29-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection. It is a prodrug for BMS-626529, which binds to the viral envelope glycoprotein gp120 and interferes with attachment of the virus to the cellular CD4 receptor.
Publictions citing BOC Sciences Products
  • >> More
1.Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Landry I1, Zhu L1, Abu Tarif M1, Hruska M1, Sadler BM2, Pitsiu M3, Joshi S4, Hanna GJ1, Lataillade M4, Boulton DW1, Bertz RJ5. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2782-9. doi: 10.1128/AAC.02503-15. Print 2016 May.
BMS-663068 is an oral prodrug of the HIV-1 attachment inhibitor BMS-626529, which prevents viral attachment to host CD4(+) T cells by binding to HIV-1 gp120. To guide dose selection for the phase 3 program, pharmacokinetic/pharmacodynamic modeling was performed using data from two phase 2 studies with HIV-1-infected subjects (n = 244). BMS-626529 population pharmacokinetics were described by a two-compartment model with first-order elimination from the central compartment, zero-order release of prodrug from the extended-release formulation into a hypothetical absorption compartment, and first-order absorption into the central compartment. The covariates of BMS-663068 formulation type, lean body mass, baseline CD8(+) T-cell percentage, and ritonavir coadministration were found to be significant contributors to intersubject variability. Exposure-response analyses showed a relationship between the loge-transformed concentration at the end of a dosing interval (Ctau) normalized for the protein binding-adjusted BMS-626529 half-maximal (50%) inhibitory concentration (PBAIC50) and the change in the HIV-1 RNA level from the baseline level after 7 days of BMS-663068 monotherapy.
2.Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L1, Hruska M2, Hwang C2, Shah V2, Furlong M2, Hanna GJ2, Bertz R2, Landry IS2. Antimicrob Agents Chemother. 2015 Jul;59(7):3816-22. doi: 10.1128/AAC.04914-14. Epub 2015 Apr 13.
BMS-663068 is a prodrug of BMS-626529, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4(+) T cells. This open-label, multiple-dose, four-sequence, crossover study addressed potential two-way drug-drug interactions following coadministration of BMS-663068 (BMS-626529 is a CYP3A4 substrate), atazanavir (ATV), and ritonavir (RTV) (ATV and RTV are CYP3A4 inhibitors). Thirty-six healthy subjects were randomized 1:1:1:1 to receive one of four treatment sequences with three consecutive treatments: BMS-663068 at 600 mg twice daily (BID), BMS-663068 at 600 mg BID plus RTV at 100 mg once daily (QD), ATV at 300 mg QD plus RTV at 100 mg QD (RTV-boosted ATV [ATV/r]), or BMS-663068 at 600 mg BID plus ATV at 300 mg QD plus RTV at 100 mg QD. Compared with the results obtained by administration of BMS-663068 alone, coadministration of BMS-663068 with ATV/r increased the BMS-626529 maximum concentration in plasma (Cmax) and the area under the concentration-time curve in one dosing interval (AUCtau) by 68% and 54%, respectively.
3.Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lalezari JP1, Latiff GH2, Brinson C3, Echevarría J4, Treviño-Pérez S5, Bogner JR6, Thompson M7, Fourie J8, Sussmann Pena OA9, Mendo Urbina FC10, Martins M11, Diaconescu IG12, Stock DA13, Joshi SR13, Hanna GJ14, Lataillade M13; AI438011 study team. Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1.
BACKGROUND: BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we present the results of the primary analysis.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HIV Products

CAS 174484-41-4 Tipranavir

(CAS: 174484-41-4)

Tipranavir, a nonpeptidic HIV protease inhibitor (NPPI), inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against mult...

CAS 155213-67-5 Ritonavir

(CAS: 155213-67-5)

Ritonavir is a very potent inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean Ki of 19 nM and also inhibits tolbutamide hydroxylation with IC5...

CAS 7481-89-2 Zalcitabine

(CAS: 7481-89-2)

Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI).

(CAS: 1443460-91-0)

GSK2838232, a derivative of Betulin, is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection.

CAS 154598-52-4 Efavirenz

(CAS: 154598-52-4)

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are highly specific and potent allosteric inhibitors of human immunodeficiency virus type 1 (HIV-1) rev...

CAS 62956-48-3 Gomisin G

Gomisin G
(CAS: 62956-48-3)

Gomisin G, carboxylic acid with additional oxygen functions, exhibited the most potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 mi...

CAS 1236287-04-9 Tenofovir maleate

Tenofovir maleate
(CAS: 1236287-04-9)

Tenofovir hydrate reduces the viral cytopathic effect of HIV-1(IIIB), HIV-2(ROD) and HIV(EHO) with EC50 of 1.15 μg/mL, 1.12 μg/mL and 1.05 μg/mL in MT-4 cells. ...

CAS 134678-17-4 Lamivudine

(CAS: 134678-17-4)

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor, used for treatment of chronic HBV and HIV/AIDS.

CAS 379270-37-8 Tenofovir Alafenamide

Tenofovir Alafenamide
(CAS: 379270-37-8)

Tenofovir Alafenamide is a prodrug of Tenofovir, which is a reverse transcriptase inhibitor used to treat HIV and Hepatitis B. Antiviral.

(CAS: 864953-33-3)

BMS-663749 is HIV-1 attachment inhibitor.

PD 134922
(CAS: 150351-30-7)

PD 134922 has been found to be a HIV-1 protease inhibitor that could probably be effective against HIV infections.

CAS 269055-15-4 Etravirine

(CAS: 269055-15-4)

Etravirine (ETR, brand name Intelence, formerly known as TMC125) is a drug used for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase i...

CAS 144217-65-2 YYA-021

(CAS: 144217-65-2)

YYA-021 enhances the neutralization sensitivity of simian-human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodefici...

CAS 869901-69-9 MK-2048

(CAS: 869901-69-9)

MK-2048 is a second generation integrase inhibitor (IC50=2.6 nM). It can inhibits the HIV enzyme integrase 4 times longer than raltegravir.

CAS 134624-73-0 Stavudine sodium

Stavudine sodium
(CAS: 134624-73-0)

Stavudine sodium is a dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Stavudine sodium is an analog of thymi...

CAS 957890-42-5 HIV-1 integrase inhibitor 2

HIV-1 integrase inhibitor 2
(CAS: 957890-42-5)

HIV-1 integrase inhibitor 2 is useful for anti-HIV, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other...

CAS 1416258-16-6 (±)-BI-D

(CAS: 1416258-16-6)

Approximately 2.4–2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160–200 ...

CAS 226700-81-8 Fosamprenavir Calcium Salt

Fosamprenavir Calcium Salt
(CAS: 226700-81-8)

HIV protease inhibitor; water soluble prodrug of amprenavir.

CAS 379270-38-9 GS-7340 fumarate

GS-7340 fumarate
(CAS: 379270-38-9)

Tenofovir alafenamide fumarate, also known as Tenofovir alafenamide hemifumarate; TAF, GS-7340, is a nucleotide reverse transcriptase inhibitor and a novel pro...

CAS 143491-57-0 Emtricitabine

(CAS: 143491-57-0)

Emtricitabine moderately reduces hepatocyte proliferation independent of effects on mtDNA in HepG2 human hepatoma cells.

Chemical Structure

CAS 864953-29-7 BMS-663068

Quick Inquiry

Verification code

Featured Items